ACUR News Alert Acura Pharmaceuticals (ACUR) 0.52 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 5:53 PM

Acura Pharmaceuticals (ACUR) 0.52 $ACUR

Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST

MNK: 97.84 (-0.29), BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Marketwired - Tue Dec 23, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE technology, in all Kmart in-store pharmacies nationwide (http://www.pharmacytimes.co m/sap-news/Kmart-Pharmacy-Takes-Step-to-Battle-Methamphetamine).
ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Marketwired - Mon Dec 08, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 8,901,113 by the United States Patent and Trademark Office.
ACUR: 0.52 (+0.02)

FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Acura Pharmaceuticals' CEO Robert Jones on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 1:23PM CST

ACUR: 0.52 (+0.02)

Acura Pharmaceuticals beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:33PM CST

ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 03, 3:31PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014.
ACUR: 0.52 (+0.02)

Acura Pharma reports November 3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:03AM CDT

ACUR: 0.52 (+0.02)

Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
Marketwired - Tue Oct 28, 10:11AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on Monday, November 3, 2014. The Company will host a conference call to discuss the results on Tuesday, November 4, 2014 at 8:30 a.m. ET.
ACUR: 0.52 (+0.02)

OTC Daily Alert Stock Watch - Acura Pharmaceuticals, Inc., (NASDAQ: ACUR)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ACUR: 0.52 (+0.02)

FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development
Marketwired - Thu Oct 16, 5:01AM CDT
Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's appeal of the position taken by Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) that abuse by snorting of hydrocodone with acetaminophen products lacks relevance. Relevance is defined in FDA's January 2013 Draft Guidance on the evaluation and labeling of abuse deterrent opioids to be a "known or expected" route of abuse for that product.
ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints
Marketwire - Mon Sep 29, 5:00AM CDT
Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION(R) hydrocodone bitartrate with acetaminophen (AVERSION H/A) development product with the key study demonstrating that AVERSION H/A met the objective of conformance with the Food and Drug Administration's (FDA) standards for bioequivalence when compared to the reference drug NORCO(R), when taken in the fasted state. A food effect was observed with the AVERSION H/A formulation with lower peak blood concentrations for both hydrocodone and acetaminophen than the comparator product.
ACUR: 0.52 (+0.02)

Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.
MNK: 97.84 (-0.29), IPXL: 31.32 (+0.26), AKRX: 36.47 (+0.43), ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone Bitartrate With Acetaminophen Tablets
Marketwire - Mon Sep 15, 5:00AM CDT
Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert(R), its abuse deterrent formulation of hydrocodone and acetaminophen tablets. The dispute pertains to the FDA's determination that nasal snorting abuse of hydrocodone with acetaminophen products lacks relevance.
ACUR: 0.52 (+0.02)

Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 41.52 (+0.51), CPRX: 2.90 (-0.02), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02), OMER: 22.09 (+0.48)

Acura Pharmaceuticals wins National Institutes of Health's grant to fund Limitx novel abuse deterrent technology
M2 - Wed Aug 27, 6:52AM CDT
Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) reported on Wednesday the receipt of a USD300,000 grant to fund Phase I development of its new, early stage Limitx abuse deterrent technology.
ACUR: 0.52 (+0.02)

Acura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology
Marketwire - Wed Aug 27, 5:15AM CDT
Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant"

by the National Institute On Drug Abuse ("NIDA"

of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx(TM) abuse deterrent technology. The Grant is based on a proposal submitted by the Company to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets.
ACUR: 0.52 (+0.02)

Mallinckrodt Acquires Questcor, to Join S&P 500 As Well - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:30PM CDT
Mallinckrodt announced the completion of its acquisition of Questcor Pharmaceuticals, Inc. in a deal valued at approximately $5.8 billion.
MNK: 97.84 (-0.29), AKRX: 36.47 (+0.43), AZN: 70.44 (+0.26), ACUR: 0.52 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...